Back to Search
Start Over
Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases
- Source :
- The Journal of Dermatology. 42:1094-1097
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- Dipeptidyl peptidase-4 inhibitors are a new class of antidiabetic agents also shown to possess immunomodulatory functions. Although various dipeptidyl peptidase-4 inhibitors have been widely used and assumed to be administrated in many patients with psoriasis accompanied by type 2 diabetic mellitus, only two studies have shown that sitagliptin, a dipeptidyl peptidase-4 inhibitor, improved the cutaneous symptom of psoriasis independently of its antihyperglycemic effect. We report two cases of psoriatic skin lesions that obviously ameliorated after initiation of therapy with teneligliptin, a novel dipeptidyl peptidase-4 inhibitor. This report strengthens the notion that dipeptidyl peptidase-4 inhibitors clinically exert an ameliorating effect on psoriatic lesions. Considering the pharmacokinetic data that indicate the high penetrative ability of teneligliptin into skin tissue, teneligliptin may be considered an effective agent for improving skin lesions of psoriasis.
- Subjects :
- Male
endocrine system diseases
Diabetic mellitus
Dermatology
Dipeptidyl peptidase-4 inhibitor
Pharmacology
Psoriatic skin
Pharmacokinetics
Psoriasis
Humans
Hypoglycemic Agents
Medicine
Teneligliptin
Antidiabetic agents
Aged
Dipeptidyl-Peptidase IV Inhibitors
business.industry
General Medicine
medicine.disease
Diabetes Mellitus, Type 2
Sitagliptin
Immunology
Pyrazoles
Thiazolidines
business
medicine.drug
Subjects
Details
- ISSN :
- 03852407
- Volume :
- 42
- Database :
- OpenAIRE
- Journal :
- The Journal of Dermatology
- Accession number :
- edsair.doi.dedup.....1cfc467f0bed4bca3135214b1eec9ac5